A head-to-head comparison suggests that GlaxoSmithKline PLC's Cervarix vaccine triggers a stronger immune response against the cervical cancer-causing human papillomavirus (HPV) than Merck & Co.'s Gardasil.
The Glaxo-funded study of 1,100 women, ages 18 to 45, didn't examine which vaccine was more effective at preventing cervical cancer or precancerous lesions, the Wall Street Journal reported.
The findings were presented at a Swedish medical conference that began Friday. Cervarix is on the market in Europe and is currently under review by the U.S. Food and Drug Administration.
Gardasil is designed to protect women against four HPV types, including those that cause most cases of genital warts, the Wall Street Journal reported. Cervarix targets two HPV types and isn't meant to provide as much protection against genital warts.